Arecor Therapeutics plc

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:01 10/09/2024 BST			5-day change	1st Jan Change
77.50 ^GBX	0.00%		-6.06%	-57.53%

07-23	Arecor Therapeutics Completes Retail Offer	MT
07-22	Arecor Therapeutics Raises GBP7 Million via Share Placing, Subscription, retail offer	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Arecor Therapeutics plc

Arecor Therapeutics Completes Retail Offer	07-23	MT
Arecor Therapeutics Raises GBP7 Million via Share Placing, Subscription, retail offer	07-22	MT
Ingenta and Shearwater win deals	07-19	AN
EARNINGS AND TRADING: Sound Energy sells part of Moroccan assets	06-14	AN
Political turmoil hits euro and banks	06-10	AN
Europe heads lower amid political turmoil in EU	06-10	AN
AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	06-10	AN
Arecor Therapeutics shares dive as says needs funding in third quarter	06-10	AN
Europe sinks, euro down amid French snap election	06-10	AN
Transcript : Arecor Therapeutics plc - Special Call	05-21
Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins	05-20	CI
Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study	05-20	MT
Arecor Therapeutics hails positive profile for insulin AT278	05-20	AN
EARNINGS AND TRADING: Michelmersh continues with positive order intake	05-16	AN
Transcript : Arecor Therapeutics plc, 2023 Earnings Call, May 16, 2024	05-16
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts FY23 Revenue GBP4.6M	05-16	MT
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Reports FY23 Loss GBP-0.28	05-16	MT
Arecor Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	05-16	CI
Arecor Therapeutics collaborates with Medtronic on novel insulin	05-09	AN
Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development	05-09	MT
Arecor and Medtronic Diabetes Collaboration	05-09	CI
Arecor Therapeutics delays publication of 2023 results	05-03	AN
Arecor Therapeutics plc Announces Delay in Publication of the Group's Final Results for the Year Ended 31 December 2023	05-03	CI
Arecor chief financial officer to leave in July after five years	04-23	AN
Arecor Therapeutics CFO to Leave in July	04-23	MT

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Employees

Sector

Biotechnology & Medical Research

Calendar

11:45am - European Association for the Study of Diabetes Meeting - Presentation Number: LBA 53

More about the company